SCHEMBL18159987

SCHEMBL18159987

Cc1[nH]nc(N/C(=N\C(=O)c2cccc(Cl)c2)Nc2cc(F)cc(Cl)c2)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.50
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
PLK4 O00444 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KIT P10721 1/20 0.36
PDGFRA P16234 1/20 0.36
KDR P35968 1/20 0.36
GRM4 Q14833 1/20 0.35
SLC6A9 P48067 1/20 0.35
SLC6A5 Q9Y345 1/20 0.35
MET P08581 1/20 0.35
PDGFRB P09619 1/20 0.35
CDK8 P49336 1/20 0.35
ROCK1 Q13464 1/20 0.35
NTRK3 Q16288 1/20 0.35
NTRK2 Q16620 1/20 0.35
AURKB Q96GD4 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18159978 0.90 CYP2D6 (0.39) CYP2D6MEN1KMT2AGRM4RAF1
SCHEMBL18162883 0.89 CYP2D6 (0.53) CYP2D6RAB9ANPC1PLK4MEN1
SCHEMBL16865704 0.86 RAB9A (0.57) CYP2D6RAB9ANPC1PLK4MEN1
SCHEMBL16865706 0.79 NPC1 (0.56) CYP2D6RAB9ANPC1PLK4SLC6A9
SCHEMBL16806293 0.79 CYP2D6 (0.56) CYP2D6RAB9ANPC1PLK4MEN1
SCHEMBL16797226 0.79 CYP2D6 (0.42) CYP2D6MEN1KMT2AGRM4CHUK
SCHEMBL16797227 0.79 CYP2D6 (0.42) CYP2D6MEN1KMT2AGRM4CHUK
SCHEMBL16794322 0.79 CYP2D6 (0.65) CYP2D6RAB9ANPC1PLK4MEN1
SCHEMBL16865709 0.79 CYP2D6 (0.65) CYP2D6RAB9ANPC1PLK4MEN1
SCHEMBL16794424 0.79 CYP2D6 (0.65) CYP2D6RAB9ANPC1PLK4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815791-B2 Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-11-14 US disclosed
US-20160304465-A1 ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304465-A1 ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME CYP2D6 1739/4885RAB9A 754/4885NPC1 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.